GlassScriptPhysician profile
Edward Young Park
NPI 1497783971
$2,303.55
in general payments reported to CMS, 2019-2025
19 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $151 · 2021: $151 · 2022: $174 · 2024: $303 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771 · Education: $22.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.52 |
| Education | $22.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $464.11 | 2019-2021 | |
| Nxstage Medical, INC. | $337.53 | 2020-2025 | Nxstage System One |
| Amgen INC. | $189.95 | 2019-2025 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $166.54 | 2021-2025 | |
| Vantive US Healthcare LLC | $148.12 | 2025 | Renal - Pd |
| Novartis Pharmaceuticals Corporation | $146.66 | 2019-2022 | |
| Nevro Corp. | $143.65 | 2019 | |
| Baxter Healthcare | $123.64 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $121.86 | 2019-2022 | |
| Vifor Pharma, INC. | $110.06 | 2019-2021 | |
| Akebia Therapeutics INC | $105.10 | 2019-2022 | |
| Glaxosmithkline, LLC. | $43.22 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.68 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $39.62 | 2019 | |
| Alexion Pharmaceuticals, INC. | $36.42 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $23.23 | 2019 | |
| Travere Therapeutics, INC. | $22.70 | 2024-2025 | Filspari |
| Genzyme Corporation | $19.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.